Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 10/20 | 0.40 |
| ▸ | MTOR | P42345 | 6/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.34 |
| ▸ | FEN1 | P39748 | 5/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 2/20 | 0.33 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25437180 | 1.00 | PIK3CA (0.40) | PIK3CAMTORL3MBTL1FLT3ALOX5AP | |
| SCHEMBL25435602 | 0.91 | ALDH1A1 (0.37) | PIK3CAL3MBTL1ALOX5APFEN1SCN1A | |
| SCHEMBL25435598 | 0.91 | ALDH1A1 (0.37) | PIK3CAL3MBTL1ALOX5APFEN1SCN1A | |
| SCHEMBL30438495 | 0.86 | PIK3CA (0.41) | PIK3CAMTORL3MBTL1FLT3ALOX5AP | |
| SCHEMBL25701931 | 0.86 | PIK3CA (0.41) | PIK3CAMTORL3MBTL1FLT3ALOX5AP | |
| SCHEMBL30438339 | 0.78 | TGFBR1 (0.38) | PIK3CAMTORALOX5APFEN1SCN1A | |
| SCHEMBL25701645 | 0.78 | TGFBR1 (0.38) | PIK3CAMTORALOX5APFEN1SCN1A | |
| SCHEMBL25703348 | 0.78 | SCN1A (0.35) | PIK3CAMTORALOX5APFEN1SCN1A | |
| SCHEMBL30438540 | 0.78 | SCN1A (0.35) | PIK3CAMTORALOX5APFEN1SCN1A | |
| SCHEMBL31529527 | 0.77 | ALDH1A1 (0.37) | PIK3CAMTORALOX5APFEN1SCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LTD (GB) | 2025-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CACNA1A, CACNA1E, CACNA1S | PIK3CA 2125/4885MTOR 714/4885L3MBTL1 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.